SCHEMBL4234002

SCHEMBL4234002

COc1ccc(-c2cc3cc(O[Si](C)(C)C(C)(C)C)ccc3o2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 3/20 0.60
▸ CA12 O43570 4/20 0.56
▸ CA1 P00915 4/20 0.56
▸ CA9 Q16790 4/20 0.56
▸ HIF1A Q16665 1/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ NFKB1 P19838 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ NFKB2 Q00653 2/20 0.47
▸ RELA Q04206 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14833013 0.84 APP (0.82) APPNPC1MAPTNFKB1RAB9A
SCHEMBL29873198 0.84 APP (0.82) APPNPC1MAPTNFKB1RAB9A
SCHEMBL4448303 0.79 APP (0.61) APPHIF1ANPC1MAPTNFKB1
SCHEMBL1143874 0.79 GABRP (0.66) APPNPC1MAPTNFKB1RAB9A
SCHEMBL13672844 0.79 APP (0.64) APPNPC1MAPTNFKB1RAB9A
SCHEMBL11733647 0.77 MAOB (0.67) APPNPC1MAPTNFKB1RAB9A
SCHEMBL11844763 0.77 APP (0.75) APPNPC1MAPTNFKB1RAB9A
SCHEMBL3933612 0.76 ESR1 (0.47) APPCA12CA1CA9MAOB
SCHEMBL7363983 0.76 PREP (0.54) CA12CA1CA9NPC1RAB9A
SCHEMBL735788 0.76 APP (0.73) APPNPC1MAPTNFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R APP 225/4885CA12 4608/4885CA1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback